PL3183260T3 - Modyfikowane oligonukleotydy i sposoby ich syntezy - Google Patents
Modyfikowane oligonukleotydy i sposoby ich syntezyInfo
- Publication number
- PL3183260T3 PL3183260T3 PL14838930T PL14838930T PL3183260T3 PL 3183260 T3 PL3183260 T3 PL 3183260T3 PL 14838930 T PL14838930 T PL 14838930T PL 14838930 T PL14838930 T PL 14838930T PL 3183260 T3 PL3183260 T3 PL 3183260T3
- Authority
- PL
- Poland
- Prior art keywords
- synthesis
- methods
- modified oligonucleotides
- oligonucleotides
- modified
- Prior art date
Links
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/52—Nitrogen atoms not forming part of a nitro radical with hetero atoms directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2014134380A RU2708237C2 (ru) | 2014-08-22 | 2014-08-22 | Модифицированные олигонуклеотиды и способ их получения |
| EP14838930.7A EP3183260B1 (en) | 2014-08-22 | 2014-08-28 | Modified oligonucleotides and methods for their synthesis |
| PCT/RU2014/000647 WO2016028187A1 (en) | 2014-08-22 | 2014-08-28 | Modified oligonucleotides and methods for their synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3183260T3 true PL3183260T3 (pl) | 2021-11-08 |
Family
ID=52589739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14838930T PL3183260T3 (pl) | 2014-08-22 | 2014-08-28 | Modyfikowane oligonukleotydy i sposoby ich syntezy |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11208430B2 (pl) |
| EP (2) | EP3183260B1 (pl) |
| JP (1) | JP6632605B2 (pl) |
| KR (1) | KR102143384B1 (pl) |
| CN (2) | CN106795197B (pl) |
| DK (1) | DK3183260T3 (pl) |
| ES (1) | ES2877560T3 (pl) |
| PL (1) | PL3183260T3 (pl) |
| PT (1) | PT3183260T (pl) |
| RU (1) | RU2708237C2 (pl) |
| WO (1) | WO2016028187A1 (pl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2708237C2 (ru) * | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
| AU2016334232B2 (en) | 2015-10-09 | 2022-05-26 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| MA45270A (fr) * | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| RU2769249C2 (ru) | 2016-07-05 | 2022-03-29 | Биомарин Текноложис Б.В. | Олигонуклеотиды, производящие переключение или модулирование сплайсинга пре-рнк и содержащие бициклические каркасные фрагменты, с улучшенными характеристиками для лечения генетических заболеваний |
| RU2016138168A (ru) * | 2016-09-26 | 2018-03-29 | Оксфордский Университет | Аналоги олигонуклеотидов как средства коррекции сплайсинга для лечения мышечной дистрофии дюшена |
| EP3519467B1 (en) | 2016-09-30 | 2021-03-17 | Dow Global Technologies LLC | Bis-phosphaguanidine and poly-phosphaguanidine ligands with group iv metal catalysts produced therefrom |
| RU2698134C2 (ru) | 2017-12-04 | 2019-08-22 | Общество с ограниченной ответственностью "Биолабмикс" | Способ амплификации нуклеиновых кислот с использованием фосфорилгуанидиновых олигонуклеотидов |
| JP2020524485A (ja) | 2017-06-02 | 2020-08-20 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| CN111050806A (zh) | 2017-06-02 | 2020-04-21 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| WO2019200185A1 (en) * | 2018-04-12 | 2019-10-17 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| KR20210018267A (ko) | 2018-05-07 | 2021-02-17 | 알닐람 파마슈티칼스 인코포레이티드 | 간외 전달 |
| WO2019217784A1 (en) * | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| JP2022513719A (ja) * | 2018-12-06 | 2022-02-09 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
| US20220125934A1 (en) | 2018-12-07 | 2022-04-28 | Oxford University Innovation Limited | Linkers |
| GB201911403D0 (en) | 2019-08-09 | 2019-09-25 | Univ Oxford Innovation Ltd | Conjugate and uses thereof |
| CN114555621A (zh) | 2019-08-15 | 2022-05-27 | Ionis制药公司 | 键修饰的寡聚化合物及其用途 |
| CN110627679A (zh) * | 2019-10-15 | 2019-12-31 | 安徽昊帆生物有限公司 | 有机叠氮类离子型化合物及其制备方法 |
| RU2738093C9 (ru) * | 2019-12-23 | 2020-12-29 | Общество с ограниченной ответственностью "Гелеспон" | Способ синтеза 2'-о-(2-метоксиэтил) тиофосфатного олигонуклеотида |
| JP2023515862A (ja) * | 2020-03-01 | 2023-04-14 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
| WO2022081046A1 (ru) * | 2020-10-12 | 2022-04-21 | Максим Сергеевич КУПРЮШКИН | Химическое соединение с триазиновой группой и способ его получения |
| AU2022312170A1 (en) | 2021-07-16 | 2024-02-08 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Oligonucleotide for inhibiting quaking activity |
| GB202205213D0 (en) | 2022-04-08 | 2022-05-25 | Univ Oxford Innovation Ltd | Lysine rich cell-penetrating peptides |
| AR129237A1 (es) | 2022-05-06 | 2024-07-31 | Academisch Ziekenhuis Leiden | OLIGONUCLEÓTIDOS DE UNIÓN A ARNm DE POLIOMAVIRUS |
| WO2024022911A1 (en) | 2022-07-25 | 2024-02-01 | Vico Therapeutics B.V. | Antisense oligonucleotides for treating a disease or condition associated with an abnormal processing of app |
| GB202216207D0 (en) | 2022-11-01 | 2022-12-14 | Univ Oxford Innovation Ltd | Shortened cell-penetrating peptides |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3634555A (en) * | 1969-07-31 | 1972-01-11 | Du Pont | Phosphorylguanidine esters |
| FR2092794B1 (pl) * | 1970-06-19 | 1974-03-22 | Ugine Kuhlmann | |
| US4154826A (en) * | 1976-12-30 | 1979-05-15 | Ciba-Geigy Corporation | Thiophosphorylguanidines for combating pests |
| WO1989009221A1 (en) * | 1988-03-25 | 1989-10-05 | University Of Virginia Alumni Patents Foundation | Oligonucleotide n-alkylphosphoramidates |
| US5475096A (en) | 1990-06-11 | 1995-12-12 | University Research Corporation | Nucleic acid ligands |
| US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| CA2382499A1 (en) | 1999-08-27 | 2001-03-08 | Medical Research Council | Method for coupling molecules |
| WO2003002587A2 (en) * | 2001-06-29 | 2003-01-09 | Micrologix Biotech Inc. | Phosphoramide containing nucleic acid-based compounds and libraries as antivirals |
| US7427675B2 (en) * | 2004-08-23 | 2008-09-23 | Isis Pharmaceuticals, Inc. | Compounds and methods for the characterization of oligonucleotides |
| DE502005008153D1 (de) * | 2005-11-23 | 2009-10-29 | Roche Diagnostics Gmbh | Polynukleotid mit Phosphatmimetikum |
| CA2676115C (en) * | 2007-04-18 | 2011-09-20 | F. Hoffmann-La Roche Ag | Nucleotide with an alpha-phosphate mimetic |
| WO2008141799A1 (en) | 2007-05-24 | 2008-11-27 | Roche Diagnostics Gmbh | Oligophosphoramidates |
| DK2285819T3 (da) * | 2008-04-04 | 2013-12-02 | Isis Pharmaceuticals Inc | Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider |
| US8575305B2 (en) | 2008-06-04 | 2013-11-05 | Medical Research Council | Cell penetrating peptides |
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| US9744183B2 (en) | 2009-07-06 | 2017-08-29 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
| DK2734208T3 (en) | 2011-07-19 | 2017-06-19 | Wave Life Sciences Ltd | PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS |
| EP2872485B1 (en) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| RU2015104762A (ru) | 2012-07-13 | 2018-08-31 | Уэйв Лайф Сайенсес Лтд. | Хиральный контроль |
| PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
| RU2708237C2 (ru) * | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
| RU2016138168A (ru) | 2016-09-26 | 2018-03-29 | Оксфордский Университет | Аналоги олигонуклеотидов как средства коррекции сплайсинга для лечения мышечной дистрофии дюшена |
| RU2740501C2 (ru) | 2017-02-21 | 2021-01-14 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | МОДИФИЦИРОВАННЫЕ ОЛИГОНУКЛЕОТИДЫ, АКТИВИРУЮЩИЕ РНКазу Н |
| RU2698134C2 (ru) | 2017-12-04 | 2019-08-22 | Общество с ограниченной ответственностью "Биолабмикс" | Способ амплификации нуклеиновых кислот с использованием фосфорилгуанидиновых олигонуклеотидов |
| CN111050806A (zh) | 2017-06-02 | 2020-04-21 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| CA3072076A1 (en) | 2017-08-08 | 2019-02-14 | Chandra Vargeese | Oligonucleotide compositions and methods thereof |
| WO2019200185A1 (en) | 2018-04-12 | 2019-10-17 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2019217784A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11686884B2 (en) | 2018-12-07 | 2023-06-27 | Apple Inc. | Light-absorbing flange lenses |
| CA3134036A1 (en) | 2019-03-20 | 2020-09-24 | Wave Life Sciences Ltd. | Technologies useful for oligonucleotide preparation |
-
2014
- 2014-08-22 RU RU2014134380A patent/RU2708237C2/ru not_active Application Discontinuation
- 2014-08-28 EP EP14838930.7A patent/EP3183260B1/en active Active
- 2014-08-28 PL PL14838930T patent/PL3183260T3/pl unknown
- 2014-08-28 JP JP2017506282A patent/JP6632605B2/ja active Active
- 2014-08-28 CN CN201480081300.5A patent/CN106795197B/zh active Active
- 2014-08-28 EP EP21164007.3A patent/EP3904364A1/en active Pending
- 2014-08-28 US US15/329,764 patent/US11208430B2/en active Active
- 2014-08-28 DK DK14838930.7T patent/DK3183260T3/da active
- 2014-08-28 WO PCT/RU2014/000647 patent/WO2016028187A1/en active Application Filing
- 2014-08-28 ES ES14838930T patent/ES2877560T3/es active Active
- 2014-08-28 KR KR1020177005653A patent/KR102143384B1/ko active IP Right Grant
- 2014-08-28 CN CN202210675338.1A patent/CN115010780A/zh active Pending
- 2014-08-28 PT PT148389307T patent/PT3183260T/pt unknown
-
2020
- 2020-09-04 US US17/012,948 patent/US20210032283A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN106795197B (zh) | 2022-06-28 |
| PT3183260T (pt) | 2021-07-05 |
| JP2017527277A (ja) | 2017-09-21 |
| DK3183260T3 (da) | 2021-06-21 |
| US20210032283A1 (en) | 2021-02-04 |
| CN106795197A (zh) | 2017-05-31 |
| CN115010780A (zh) | 2022-09-06 |
| KR102143384B1 (ko) | 2020-08-12 |
| ES2877560T3 (es) | 2021-11-17 |
| KR20170043543A (ko) | 2017-04-21 |
| RU2014134380A (ru) | 2016-03-20 |
| EP3183260A1 (en) | 2017-06-28 |
| EP3904364A1 (en) | 2021-11-03 |
| EP3183260B1 (en) | 2021-03-31 |
| JP6632605B2 (ja) | 2020-01-22 |
| US11208430B2 (en) | 2021-12-28 |
| RU2708237C2 (ru) | 2019-12-05 |
| WO2016028187A1 (en) | 2016-02-25 |
| US20170362270A1 (en) | 2017-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3183260T (pt) | Oligonucleótidos modificados e métodos para a sua síntese | |
| IL290096A (en) | Processes for the insemination series and their uses | |
| ZA201701246B (en) | Synthesis of dna | |
| LT3215147T (lt) | Neurologinį poveikį mažinantys norketamino junginiai ir būdai | |
| SG11201608605QA (en) | Methods and means for enhancing rna production | |
| GB201410907D0 (en) | No details | |
| GB201413086D0 (en) | Methods | |
| HK1243342A1 (zh) | 化合物和方法 | |
| GB201518382D0 (en) | Catalyst and process | |
| GB201409250D0 (en) | New product | |
| SG11201701118TA (en) | Improved process for alaknolamide synthesis | |
| GB201408745D0 (en) | Methods | |
| SG11201700652PA (en) | Modified antimir-138 oligonucleotides | |
| GB201419650D0 (en) | Modified heterocyclase | |
| PL3423594T3 (pl) | Oligonukleotydy i sposoby ich przygotowania | |
| GB201410910D0 (en) | No details | |
| GB201415685D0 (en) | Methods | |
| GB201402910D0 (en) | Hopper | |
| GB201421747D0 (en) | Analysis and synthesis flexi-unit | |
| GB201408729D0 (en) | Synthesis | |
| GB201403353D0 (en) | Novel oligonucleotides | |
| GB201403087D0 (en) | Novel oligonucleotides | |
| TWM489526U (en) | Improved structure for ornament | |
| GB201416951D0 (en) | Method of synthesis | |
| GB201414122D0 (en) | Methods |